Brokerage firm Barclays Maintains its rating on The Advisory Board Company(NASDAQ:ABCO). In a research note issued to the investors, the brokerage major Raises the price-target to $50.00 per share. The shares have been rated Overweight. The rating by Barclays was issued on Sep 30, 2016.
In a different note, On Jul 28, 2016, Barclays said it Maintains its rating on The Advisory Board Company. In the research note, the firm Raises the price-target to $41.00 per share. The shares have been rated ‘Overweight’ by the firm. On Jul 28, 2016, Craig-Hallum said it Upgrades its rating on The Advisory Board Company. The shares have been rated ‘Buy’ by the firm. On Jul 19, 2016, Raymond James said it Downgrades its rating on The Advisory Board Company. The shares have been rated ‘Market Perform’ by the firm.
The Advisory Board Company (ABCO) shares turned negative on Tuesdays trading session with the shares closing down -0.05 points or -0.11% at a volume of 1,24,434. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $43.73. The peak price level was also seen at $43.73 while the days lowest was $43.13. Finally the shares closed at $43.45. The 52-week high of the shares is $54.835 while the 52-week low is $18.87. According to the latest information available, the market cap of the company is $1,749 M.
The Advisory Board Company(ABCO) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $198.38M. Analysts had an estimated revenue of $196.49M. Earnings per share were $0.47. Analysts had estimated an EPS of $0.34.
Several Insider Transactions has been reported to the SEC. On Sep 22, 2016, Michael T Kirshbaum (Chief Financial Officer) sold 2,400 shares at $43.01 per share price.Also, On Sep 16, 2016, Cormac F Miller (Chief Product Officer) sold 1,500 shares at $43.04 per share price.On Sep 14, 2016, Robert W Musslewhite (Chief Executive Officer) sold 5,500 shares at $43.09 per share price, according to the Form-4 filing with the securities and exchange commission.
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues including physician alignment and engagement network management and growth strategy value-based care and population health revenue cycle clinical operations and supply chain. Its higher education programs support colleges and universities in enrollment management academic programming and student learning faculty recruitment and retention student advising and success alumni affairs and advancement and college and university operations. The Company offers approximately 65 distinct membership programs across four areas which include best practices research and insight performance technology software consulting and management services and data- and tech-enabled services. Its best practices research and insight programs provide the foundation for all of its other programs.